Renal denervation in the treatment of hypertension

Current Hypertension Reports

Volumn 15, Issue 4, 2013, Pages 363-369

  Ukena, Christian ^a   Mahfoud, Felix ^a   Ewen, Sebastian ^a   Cremers, Bodo ^a   Laufs, Ulrich ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Diabetes; Heart failure; Heart rate; Patient selection; Renal denervation; Resistant hypertension; Sympathetic activity; Symplicity

Indexed keywords

ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE REGULATION; CLINICAL EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RATE; HUMAN; HYPERINSULINEMIA; HYPERTENSION; KIDNEY DENERVATION; KIDNEY FUNCTION; NONHUMAN; PATIENT SELECTION; PLEIOTROPY; PULMONARY VEIN ISOLATION; SYMPATHETIC TONE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; HYPERTENSION; KIDNEY; PATIENT SELECTION; SYMPATHECTOMY;

EID: 84880921294     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-013-0363-2     Document Type: Article

References (50)

1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-87.
2. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-42.
3. DiBona GF. Physiology in perspective: the wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol. 2005;289(3):R633-41.
4. Sobotka PA, Mahfoud F, Schlaich MP, Hoppe UC, Böhm M, Krum H. Sympatho-renal axis in chronic disease. Clin Res Cardiol. 2011;100(12):1049-57.
5. Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13(6 Pt 2):99S-105S.
6. Investigators SH-. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-7.
7. •• The Symplicity HTN-2 Investigators, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903-9. Landmark trial investigating the effects of renal denervation on blood pressure in resistant hypertension in a randomized controlled study design.
8. DiBona GF. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens. 2002;11(2):197-200.
9. DiBona GF. Neural control of the kidney: past, present, and future. Hypertension. 2003;41(3 Pt 2):621-4.
10. Converse Jr RL, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912-8.
11. O'Hagan KP, Thomas GD, Zambraski EJ. Renal denervation decreases blood pressure in DOCA-treated miniature swine with established hypertension. Am J Hypertens. 1990;3(1):62-4.
12. Kassab S, Kato T, Wilkins FC, Chen R, Hall JE, Granger JP. Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension. 1995;25(4 Pt 2):893-7.
13. Mancia G, Bousquet P, Elghozi JL, Esler M, Grassi G, Julius S, et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens. 2007;25(5):909-20.
14. Norman Jr RA, Murphy WR, Dzielak DJ, Khraibi AA, Carroll RG. Role of the renal nerves in one-kidney, one clip hypertension in rats. Hypertension. 1984;6(5):622-6.
15. Page IH, Heuer GJ. The effect of renal denervation on the level of arterial blood pressure and renal function in essential hypertension. J Clin Invest. 1935;14(1):27-30.
16. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152(16):1501-4.
17. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275-81.
18. Krum H, Schlaich M, Sobotka P, Esler M, Mahfoud F, Böhm M, et al. TCT-12 long-term follow-up of catheter-based renal denervation for resistant hypertension confirms durable blood pressure reduction. J Am Coll Cardiol. 2012. doi: 10.1016/j.jacc.2012.08.017.
19. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361(9):932-4.
20. Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126(25):2976-82.
21. Ukena C, Cremers B, Ewen S, Böhm M, Mahfoud F. Non-response after renal denervation: Who is the ideal candidate? EuroIntervention 2013. doi: 10.4244/EIJV9SRA0.
22. Mahfoud F, Cremers B, Janker J, Link B, Vonend O, Ukena C, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60(2):419-24.
23. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380(9843):778.
24. Kaltenbach B, Id D, Franke JC, Sievert H, Hennersdorf M, Maier J, et al. Renal artery stenosis after renal sympathetic denervation. J Am Coll Cardiol. 2012;60(25):2694-5.
25. • Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012;60(3):596-606. Critical review of the current data and open questions in renal denervation.
26. Mancia G, Parati G. Office compared with ambulatory blood pressure in assessing response to antihypertensive treatment: a meta-analysis. J Hypertens. 2004;22(3):435-45.
27. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, et al. Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial. Hypertension. 2011;57(6):1069-75.
28. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, et al. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35(9):528-35.
29. Mahfoud F, Vonend O, Bruck H, Clasen W, Eckert S, Frye B, et al. Expert consensus statement on interventional renal sympathetic denervation for hypertension treatment. Dtsch Med Wochenschr. 2011;136(47):2418.
30. Schmieder RE, Redon J, Grassi G, Kjeldsen SE, Mancia G, Narkiewicz K, et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension. J Hypertens. 2012;30(5):837-41.
31. Pathak A, Girerd X, Azizi M, Benamer H, Halimi JM, Lantelme P, et al. Expert consensus: Renal denervation for the treatment of hypertension. Diagn Interv Imaging. 2012;93(5):386-94.
32. •• Mahfoud F, Lüscher T, Andersson B, Baumgartner I, Cifkova R, Dimario C, et al. Expert consensus document from the European Society of Cardiology on catheter-based renal denervation. Eur Heart J 2013. doi: 10.1093/eurheartj/eht154. Recommendations on the use of renal denervation by the European Society of Cardiology.
33. Kaltenbach B, Franke J, Bertog SC, Steinberg DH, Hofmann I, Sievert H. Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study. Catheter Cardiovasc Interv. 2013;81(2):335-9.
34. Ukena C, Mahfoud F, Spies A, Kindermann I, Linz D, Cremers B, et al. Effects of renal sympathetic denervation on heart rate and atrioventricular conduction in patients with resistant hypertension. Int J Cardiol 2012. doi: 10.1016/j.ijcard.2012.07.027.
35. Ukena C, Mahfoud F, Kindermann I, Barth C, Lenski M, Kindermann M, et al. Cardiorespiratory response to exercise after renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2011;58(11):1176-82.
36. Pokushalov E, Romanov A, Corbucci G, Artyomenko S, Baranova V, Turov A, et al. A randomized comparison of pulmonary vein isolation with versus without concomitant renal artery denervation in patients with refractory symptomatic atrial fibrillation and resistant hypertension. J Am Coll Cardiol. 2012;60(13):1163-70.
37. Vollmann D, Sossalla S, Schroeter MR, Zabel M. Renal artery ablation instead of pulmonary vein ablation in a hypertensive patient with symptomatic, drug-resistant, persistent atrial fibrillation. Clin Res Cardiol. 2013;102(4):315-8.
38. Ahmed H, Miller MA, Dukkipati SR, Cammack S, Koruth JS, Gangireddy S, et al. Adjunctive renal sympathetic denervation to modify hypertension as upstream therapy in the treatment of atrial fibrillation (H-FIB) study: Clinical Background and Study Design. J Cardiovasc Electrophysiol. 2013. doi: 10.1111/jce.12095.
39. Linz D, Mahfoud F, Schotten U, Ukena C, Neuberger HR, Wirth K, et al. Renal sympathetic denervation suppresses postapneic blood pressure rises and atrial fibrillation in a model for sleep apnea. Hypertension. 2012;60(1):172-8.
40. Linz D, Mahfoud F, Schotten U, Ukena C, Hohl M, Neuberger HR, et al. Renal sympathetic denervation provides ventricular rate control but does not prevent atrial electrical remodeling during atrial fibrillation. Hypertension. 2013;61(1):225-31.
41. • Witkowski A, Prejbisz A, Florczak E, Kadziela J, Sliwinski P, Bielen P, et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension. 2011;58(4):559-65. First study investigating the effects of renal denervation on the severity of obstructive sleep apnea.
42. Huggett RJ, Scott EM, Gilbey SG, Stoker JB, Mackintosh AF, Mary DA. Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension. Circulation. 2003;108(25):3097-101.
43. •• Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123(18):1940-6. By describing improvements of glucose metablolism Mahfoud et al. were the first to report non-blood pressure related effects after renal denervation.
44. Hasking GJ, Esler MD, Jennings GL, Burton D, Johns JA, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity. Circulation. 1986;73(4):615-21.
45. Floras JS. Sympathetic nervous system activation in human heart failure: clinical implications of an updated model. J Am Coll Cardiol. 2009;54(5):375-85.
46. Gheorghiade M, Colucci WS, Swedberg K. Beta-blockers in chronic heart failure. Circulation. 2003;107(12):1570-5.
47. Udelson JE. Ventricular remodeling in heart failure and the effect of beta-blockade. Am J Cardiol. 2004;93(9A):43B-8B.
48. Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann E, Böhm M, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59(10):901-9.
49. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847.
50. Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013;162(3):189-92.